KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Theses
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Theses
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    A Small Molecule Modulator of Hsp90 Improves Experimental Diabetic Neuropathy

    Thumbnail
    View/Open
    Urban_ku_0099M_11101_DATA_1.pdf (1.119Mb)
    Issue Date
    2010-07-30
    Author
    Urban, Michael Joseph
    Publisher
    University of Kansas
    Format
    89 pages
    Type
    Thesis
    Degree Level
    M.S.
    Discipline
    Medicinal Chemistry
    Rights
    This item is protected by copyright and unless otherwise specified the copyright of this thesis/dissertation is held by the author.
    Metadata
    Show full item record
    Abstract
    Background: Current Hsp90 inhibitors are therapeutically problematic. Although they induce a pro-survival heat shock response that promotes the refolding of damaged proteins, a confounding issue is that at these concentrations the inhibitors are cytotoxic, due to their ability to decrease the maturation of newly synthesized client proteins. KU-32 contains a novobiocin-based scaffold that binds to the C-terminal of Hsp90 and induces a pro-survival heat shock response at a concentration ~10,000 fold lower than that needed to induce neurotoxicity. This creates an optimal therapeutic window in which to operate, providing promise towards the development of novel neuroprotective agents. Objective: To evaluate whether the induction of the heat shock response through Hsp90 modulation could decrease or reverse the pathophysiological progression of diabetic peripheral neuropathy in Type-1 diabetic mice. Hypothesis: A small molecule modulator of Hsp90 will improve experimental diabetic neuropathy. Methods: After 8-12 weeks of diabetes induced by streptozotocin, the effects of weekly doses of KU-32 on several standard indices of diabetic neuropathy were measured. Results: Initial toxicity studies employing the weekly intraperitoneal administration of 2 or 20 mg/kg KU-32 to non-diabetic mice over 6 week duration did not alter motor or sensory nerve conduction velocity (MNCV/SNCV), mechanical or thermal sensitivity, or intra-epidermal nerve fiber density. Thus, the drug alone had no effect on altering common measures of neuropathy. In a 12-week intervention study, wild-type C57 Bl/6 animals receiving a weekly treatment regimen of 20 mg/kg KU-32 for 6 weeks exhibited a steady recovery to control levels in thermal and mechanical sensitivity, MNCV, and SNCV. KU-32 did not alter metabolic control. As Hsp70 is hypothesized to be a major target for KU-32, its necessity in neuroprotection was examined using Hsp70 double knockout mice (Hsp70.1/Hsp70.3). In a 12-week intervention study, Hsp70 knockout mice receiving a weekly treatment regimen of 20 mg/kg for 6 weeks displayed no improvements in thermal and mechanical sensitivity, MNCV, and SNCV. In 8-week intervention studies, animals demonstrated recoveries in sensory hypoalgesia and nerve conduction velocity deficits in a dose-dependent manner. KU-32 did not alter sensory nerve fiber innervation. Conclusions: These data suggest that hyperglycemia may adversely impact the ability of neurons to promote refolding or decrease unfolding of mildly damaged proteins. C-terminal Hsp90 modulators can improve several standard clinical indices of negative symptoms associated with small and large fiber dysfunction in the absence of improving overall metabolic control. The affects of KU-32 appear to be dose-dependent and require the presence of inducible Hsp70 for efficacy. Inducible Hsp70 is not required for the pathophysiological progression of diabetic neuropathy.
    URI
    http://hdl.handle.net/1808/6953
    Collections
    • Theses [3711]
    • Medicinal Chemistry Dissertations and Theses [58]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps